Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

Interest Coverage 0.86
ALR's Interest Coverage is ranked lower than
99.99% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.61 vs. ALR: 0.86 )
Ranked among companies with meaningful Interest Coverage only.
ALR' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 0.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

» ALR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ALR Guru Trades in Q2 2015

Steven Cohen 690,500 sh (+1309.18%)
Jim Simons 1,394,724 sh (+10.16%)
Mario Gabelli 218,400 sh (+4.92%)
Private Capital 927,113 sh (+1.74%)
Diamond Hill Capital 2,243,426 sh (-11.83%)
John Keeley 1,045,227 sh (-15.76%)
Manning & Napier Advisors, Inc 682,226 sh (-18.67%)
» More
Q3 2015

ALR Guru Trades in Q3 2015

Mario Gabelli 233,430 sh (+6.88%)
Private Capital 941,823 sh (+1.59%)
John Keeley 974,047 sh (-6.81%)
Diamond Hill Capital 2,058,095 sh (-8.26%)
Steven Cohen 557,400 sh (-19.28%)
Jim Simons 1,113,424 sh (-20.17%)
Manning & Napier Advisors, Inc 531,294 sh (-22.12%)
» More
Q4 2015

ALR Guru Trades in Q4 2015

Manning & Napier Advisors, Inc 1,481,660 sh (+178.88%)
Diamond Hill Capital 2,306,319 sh (+12.06%)
Mario Gabelli 235,430 sh (+0.86%)
John Keeley 964,189 sh (-1.01%)
Private Capital 930,548 sh (-1.20%)
Jim Simons 878,424 sh (-21.11%)
Steven Cohen 324,000 sh (-41.87%)
» More
Q1 2016

ALR Guru Trades in Q1 2016

George Soros 42,800 sh (New)
Jeremy Grantham 736,344 sh (New)
Mario Gabelli 494,105 sh (+109.87%)
Private Capital 933,725 sh (+0.34%)
Steven Cohen Sold Out
Manning & Napier Advisors, Inc Sold Out
John Keeley 713,314 sh (-26.02%)
Jim Simons 506,724 sh (-42.31%)
Diamond Hill Capital 1,052,078 sh (-54.38%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc


Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Traded in other countries:IM5.Germany,
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.

Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation incorporated on August 25,1992, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take control of their health at home, under the supervision of their healthcare providers, by connecting innovative diagnostics in the hands of patients to their healthcare providers. The Company is a provider of point-of-care diagnostics and services; and has developed a strong commercial presence in infectious disease, toxicology, cardiology and diabetes. Its products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease. Its portfolio also includes a broad array of health information solutions that increase access to critical health data, provide clinical decision support and facilitate more comprehensive performance reporting and analysis. The Company's operating segments are professional diagnostics, health information solutions and consumer diagnostics. Professional Diagnostics solutions allow patients and their healthcare providers to work together to better manage patients' chronic conditions over the continuum of care, from the hospital to home. It is generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which defined as testing or monitoring performed at home under the supervision of a medical professional. Its products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. In professional diagnostics, Company focus on point-of-care, rapid diagnostic testing and the developing patient self-testing and patient self-management markets where it can directly and immediately improve patient health outcomes. Its products include point-of-care and laboratory tests within the following areas; Infectious Disease, Toxicology, Cardiology, Diabetes, Oncology, Women's Health and Connected Device Technologies. Its health information solutions are designed to provide physicians with actionable data that allows them to make more effective decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. It offers a variety of software-based analytics, clinical decision-support tools, and accountable care programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcome

Guru Investment Theses on Alere Inc

Diamond Hill Capital Comments on Alere Inc - Mar 17, 2015

Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown.

From Diamond Hill Capital (Trades, Portfolio)’s Select Fund Q4 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Mario Gabelli Comments on Alere Inc - Nov 21, 2014

Alere Inc. (0.2% of net assets as of September 30, 2014) (ALR - $38.78 - NYSE) is the largest manufacturer of rapid, point-of-care diagnostics in the world. The company has underperformed for the past year, weighed down by manufacturing problems and a heavy debt load from questionable past acquisitions. An activist investor has been publicly pushing the company to improve operations and, after being slow to respond initially, Alere’s Board of Directors forced the company’s founder and CEO to resign on July 1. However, he has now partnered with private equity partners and is seeking to take the company private with an initial bid of $46 per share. Whatever the final outcome is, we believe positive change is in the air for Alere.

From Mario Gabelli (Trades, Portfolio)’s Asset Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Diamond Hill Capital Comments on Alere Inc - Oct 17, 2014

We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades


Forward P/E 15.65
ALR's Forward P/E is ranked lower than
99.99% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.76 vs. ALR: 15.65 )
Ranked among companies with meaningful Forward P/E only.

Valuation & Return


More Statistics

Revenue (TTM) (Mil) $2,506
EPS (TTM) $ 3.86
Short Percentage of Float3.25%
52-Week Range $31.47 - 55.99
Shares Outstanding (Mil)86.26

Analyst Estimate

Dec15 Dec16
Revenue (Mil $) 2,547 2,607
EPS ($) 2.37 2.34
EPS w/o NRI ($) 2.37 2.34
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($) 0.26 0.26
» More Articles for ALR


Articles On GuruFocus.com
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
Keeley Small Cap Value Fund 1st Quarter Commentary Apr 26 2016 
The Transformation in Alere May 22 2015 
Diamond Hill Capital Comments on Alere Inc Mar 17 2015 
Corsair Capital's Analysis of Alere Mar 06 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Mario Gabelli Comments on Alere Inc Nov 21 2014 
Mario Gabelli’s Asset Fund Q3 2014 Commentary Nov 21 2014 
Cohen Has Busy Third Quarter Nov 19 2014 

More From Other Websites
The content of the resolutions adopted by the Extraordinary General Meeting of Alior Bank SA dated... Jul 29 2016
Agreement with Telekom Romania Mobile Communications S.A. with its registered office in Bucharest... Jul 29 2016
Satisfaction of the condition provided for in the Share Purchase and Demerger Agreement of Bank BPH... Jul 29 2016
Ford and Whole Foods skid, Alere and Facebook jump Jul 28 2016
Here's a Reason Why Alere (ALR) Stock Is Soaring Today Jul 28 2016
[$$] Alere Faces Criminal Probe Over Medicare, Medicaid Billing Jul 28 2016
Why ConocoPhillips, Amgen, Alere & Three Other Stocks Are Trending Today Jul 28 2016
​Alere loses $1B of value in 20 minutes after reports of new federal subpoena Jul 28 2016
Faber Report: Alere shares soar Jul 28 2016
Alere Faces Criminal Probe Over Medicare, Medicaid Billing Jul 27 2016
Alere Comments on Pain Management Subpoena Jul 27 2016
7:09 pm Alere confirms receipt of a DOJ subpoena addressed to Alere Toxicology Services, Inc. on... Jul 27 2016
Alere Comments on Pain Management Subpoena Jul 27 2016
Diagnostic tester Alere plunges on reports of second front in criminal probe Jul 27 2016
Alere shares plummet after feds launch criminal probe into billing Jul 27 2016
Alere faces criminal probe over Medicare, Medicaid Billing - WSJ Jul 27 2016
Alere (ALR) Stock Plunged on Criminal Probe, CNBC's DeAngelis Says Jul 27 2016
Alere Plunges by Record on Report of U.S. Criminal Probe Jul 27 2016
Position of the Management Board of Alior Bank S.A. on the Demerger of Bank BPH S.A. Jul 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)